Notice NOT-GM-21-036 from the NIH Guide for Grants and Contracts

Funding Opportunity RFA-HG-21-008 from the NIH Guide for Grants and Contracts. The National Human Genome Research Institute intends to promote a new initiative by publishing a Request for Applications to solicit R43/R44 applications for research in the area of Transformative Nucleic Acid Sequencing Technology Innovation and Early Development: The purpose of the RFA is to refocus and emphasize NHGRIs investment in nucleic acid sequencing technology on novel technology innovation and early development. This Notice is being provided to allow potential applicants sufficient time to develop effective collaborations and responsive projects. The FOA is expected to be published in the winter of 2021 with an expected application due date in the summer of 2021.

Funding Opportunity RFA-HG-21-007 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) solicits R21 grant applications to innovate and develop the early stages of novel technologies that will enable greater than a one order of magnitude improvement in 1) DNA sequencing, and 2) methods for direct sequencing of the diversity of entire RNA molecules. Advances in genomics and more broadly in biomedical research have been greatly facilitated by cycles of technology innovation and disruption that have driven significant and sustained nucleic acid sequencing throughput and assembly quality increases combined with cost decreases and quality improvements. The goal now is to dramatically advance DNA sequencing and direct RNA sequencing technologies at reasonable costs with the anticipation that significant exploratory innovation in any of these and related areas would make significant contributions to the mission of NHGRI and the field of genomics, including to many of NHGRIs other technology development goals

Funding Opportunity RFA-HG-21-006 from the NIH Guide for Grants and Contracts. The National Human Genome Research Institute intends to promote a new initiative by publishing a Request for Applications to solicit R01 applications for research in the area of Transformative Nucleic Acid Sequencing Technology Innovation and Early Development: The purpose of the RFA is to refocus and emphasize NHGRIs investment in nucleic acid sequencing technology on novel technology innovation and early development. This Notice is being provided to allow potential applicants sufficient time to develop effective collaborations and responsive projects. The FOA is expected to be published in the winter of 2021 with an expected application due date in the summer of 2021.

Notice NOT-OD-21-090 from the NIH Guide for Grants and Contracts

Notice NOT-MD-21-017 from the NIH Guide for Grants and Contracts

Notice NOT-HL-21-009 from the NIH Guide for Grants and Contracts

Notice NOT-NS-21-050 from the NIH Guide for Grants and Contracts

Funding Opportunity RFA-HD-22-019 from the NIH Guide for Grants and Contracts. The purpose of this Funding Opportunity Announcement (FOA) is to invite SBIR applications to study/identify characteristics that inform acceptability, desirability, and excitement of potential end-users of novel contraceptive products currently in the development pipeline for both men and women.

Notice NOT-OD-21-095 from the NIH Guide for Grants and Contracts

Notice NOT-CA-21-045 from the NIH Guide for Grants and Contracts

Funding Opportunity PAR-21-162 from the NIH Guide for Grants and Contracts. The Blueprint Neurotherapeutics Network for Biologics (BPN-Biologics) provides support for biologic-based therapeutic discovery and development, from lead optimization through phase I clinical testing. This Funding Opportunity Announcement (FOA) supports preclinical discovery and development of potential therapeutic Biotechnology Products and Biologics including, but not limited to, large biologic macromolecules, (e.g., proteins, antibodies, and peptides), gene-based therapies (i.e., oligonucleotide- and viral-based), cell therapies, and novel emerging therapies (e.g., microbial and microbiome therapies). Applicants will collaborate with NIH-funded consultants and can augment their project with NIH contract research organizations (CROs) that specialize in manufacturing, scaling, pharmacokinetics, toxicology, and Phase I clinical testing. BPN-Biologics awardee institutions retain their assignment of IP rights and gain assignment of IP rights from the BPN-Biologics contractors (and thereby control the patent prosecution and licensing negotiations) for biotherapeutic candidates developed in this program.

Notice NOT-DA-21-001 from the NIH Guide for Grants and Contracts

Notice NOT-OD-21-097 from the NIH Guide for Grants and Contracts

Notice NOT-HD-21-017 from the NIH Guide for Grants and Contracts

Funding Opportunity RFA-DK-21-015 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) invites applications from institutions/organizations that propose to establish core centers that are part of an integrated and existing program of nutrition and/or obesity research. The Nutrition Obesity Research Centers (NORC) program is designed to support and enhance the national research effort in nutrition and obesity.NORCs support three primary research-related activities:Research Core services, a Pilot and Feasibility (P and F) program, and an Enrichment program. All activities pursued by Nutrition Obesity Research Centers are designed to enhance the efficiency, productivity, effectiveness and multidisciplinary nature of research in nutrition and obesity.

Notice NOT-TW-21-005 from the NIH Guide for Grants and Contracts

Notice NOT-CA-21-049 from the NIH Guide for Grants and Contracts

Notice NOT-AI-21-040 from the NIH Guide for Grants and Contracts

Notice NOT-OD-21-083 from the NIH Guide for Grants and Contracts